JinHeng Lin is an early-career postdoctoral scientist funded by the British Heart Foundation. His projects explore the effects of endogenous peptides on the regulation of coronary microvascular function, with particular focus on ion channels and endothelium-dependent mechanisms.

Estéfano Pinilla, PhD, is an Assistant Professor of Pharmacology at Aarhus University (Department of Biomedicine), currently undertaking a research stay at the Baker Heart & Diabetes Institute in Melbourne supported by a Novo Nordisk Foundation fellowship. His research focuses on endothelial biology and vascular dysfunction in metabolic disease, with particular interest in the therapeutic modulation of Transglutaminase 2 (TG2) and nitric oxide–dependent vasorelaxation. He is also active in translational science and early-stage biotech initiatives.

Chris Garland is Professor of Vascular Pharmacology at Oxford University, Fellow and Tutor in Medicine and Biomedical Science at Magdalen College, Oxford and Senior Dean of Arts, Magdalen College. He also holds visiting professorships at the University of Queensland, Australia and the University of Hong Kong. His research investigates how the very small endothelial cells lining the vasculature of the body control the flow and pressure of the blood. Among other discoveries, his group found that EDH is generated by two types of endothelial cell potassium channel, SKCa and IKCa. The British Pharmacological Society recognized his research contributions with the award of the 2009 JR Vane Medal. He has served on numerous UK grant-awarding bodies, including the Medical Research Council (Molecular and Cellular Medicines Board, Physiological Systems and Clinical Sciences Board), the Wellcome Trust (Physiology and Pharmacology Panel) and the British Heart Foundation (BHF Project Grants Committee).

Tayla Bishop is a PhD candidate in the Baker Department of Cardiometabolic Health at The University of Melbourne. She completed her Bachelor of Biomedical Science (Honours) at The University of Queensland. Her research focuses on heart failure with preserved ejection fraction (HFpEF), with a particular interest in sex-based differences in disease phenotype and therapeutic response. She integrates human biospecimens, in vitro cell-based systems, and in vivo mouse models to investigate mechanisms driving HFpEF progression and to evaluate therapeutic efficacy. Her PhD project examines whether pharmacotherapies that enhance cardioprotective signalling via the nitric oxide/cyclic guanosine monophosphate (NO/cGMP) pathway can effectively treat HFpEF, with a specific focus on improving outcomes for females.

Prof. Dr. Jens Schlossmann is Professor of Pharmacology and Toxicology at the University of Regensburg (Germany). He studied Chemistry at the universities of Tübingen and LMU Munich and completed his PhD and habilitation in Munich. He is a certified “Fachpharmakologe” of the German Pharmacological Society and author of about 80 scientific publications. His research focuses on NO/cGMP-mediated signal transduction and its molecular and (patho)physiological roles, particularly in the cardiovascular system, platelets, and kidney. In 2023, he received the PHOENIX Pharmacy Science Award for Pharmacology and Clinical Pharmacy.